MindMaze Therapeutics Holding's total inventories for the quarter that ended in Dec. 2025 was CHF1.14 Mil. MindMaze Therapeutics Holding's average total inventories from the quarter that ended in Dec. 2024 to the quarter that ended in Dec. 2025 was CHF0.57 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. MindMaze Therapeutics Holding's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was CHF-0.02.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
MindMaze Therapeutics Holding's Days Inventory for the
six
months ended in Dec. 2025 was 2,043.28.
Inventory Turnover measures how fast the company turns over its inventory within a year.
MindMaze Therapeutics Holding's Inventory Turnover for the quarter that ended in Dec. 2025 was 0.09.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
MindMaze Therapeutics Holding's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.89.
MindMaze Therapeutics Holding (CHIX:MMTXz) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
MindMaze Therapeutics Holding's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
MindMaze Therapeutics Holding's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
MindMaze Therapeutics Holding Total Inventories Related Terms
MindMaze Therapeutics Holding Total Inventories Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MindMaze Therapeutics Holding Total Inventories Chart
MindMaze Therapeutics Holding Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
What does a Total Inventories of CHF1.14 Mil mean?
MindMaze Therapeutics Holding (CHIX:MMTXZ) has a Total Inventories of CHF1.14 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for MindMaze Therapeutics Holding and its competitors.
Is MindMaze Therapeutics Holding's Total Inventories too high?
MindMaze Therapeutics Holding's current Total Inventories is CHF1.14 Mil. Overall, MindMaze Therapeutics Holding has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's Total Inventories compare to VRTX and REGN?
MindMaze Therapeutics Holding's Total Inventories of CHF1.14 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for MindMaze Therapeutics Holding and its competitors. MindMaze Therapeutics Holding's current Total Inventories is CHF1.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (CHIX:MMTXZ) has a current Total Inventories of CHF1.14 Mil. The current Total Inventories is CHF1.14 Mil. MindMaze Therapeutics Holding's overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For MindMaze Therapeutics Holding (CHIX:MMTXZ), the current Total Inventories is CHF1.14 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MindMaze Therapeutics Holding Business Description
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
15GF Score
Get the complete analysis for CHIX:MMTXZ
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:MMTXZ has been successfully added to your 